FTH
Faeth Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+12/100
Last price
26.89
▼ 0.21 (0.77%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
27.10
Day high
29.60
Day low
26.00
Volume
289.15K
Market cap
$694.85M
P/E (TTM)
—
52W range
7.45 – 42.14
Trailing performance
Returnvs SPY
1W
-4.20%
-6.2%
1M
-32.86%
-34.0%
3M
-4.03%
-8.6%
6M
-10.93%
-29.1%
YTD
+152.01%
+137.8%
1Y
+181.57%
+165.2%
3Y
+68.06%
-14.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on FTH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+883.06K
Net buying
Buy transactions
10
956.13K shares
Sell transactions
5
73.07K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.28M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 13.63K | $326.13K | Indirect |
| Jun 26, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 15.64K | $401.27K | Indirect |
| Jun 23, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 17.41K | $405.92K | Indirect |
| Jun 22, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
CONVERSION | 53.47K | $62.02K | Direct |
| Jun 22, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
BUY | 2.81K | $55.45K | Direct |
| Jun 15, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
— | 761.43K | — | Direct |
| Jun 15, 26 | HAHN STEPHEN M Director |
— | 44.76K | — | Direct |
| Jun 1, 26 | PEYER JAMES Beneficial Owner of more than 10% of a Class of Security |
SELL | 25.00K | $500.54K | Direct |
| Jun 1, 26 | CAMBRIAN BIOPHARMA INC Beneficial Owner of more than 10% of a Class of Security |
SELL | 25.00K | $500.54K | Direct |
| Apr 7, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.21K | $141.36K | Indirect |
| Apr 7, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 17.08K | $538.11K | Indirect |
| Apr 1, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 12.18K | $386.31K | Indirect |
| Apr 1, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 2.74K | $86.28K | Indirect |
| Mar 30, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 30.59K | $818.26K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CAMBRIAN BIOPHARMA INC |
Beneficial Owner of more than 10% of a Class of Security | 130.14K | Sale |
HAHN STEPHEN M |
Director | 44.76K | Conversion of Exercise of derivative security |
MILLENNIUM MANAGEMENT, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
PARIKH ANAND KIRAN J.D. |
Chief Executive Officer | 817.70K | Conversion of Exercise of derivative security |
PEYER JAMES |
Beneficial Owner of more than 10% of a Class of Security | 130.14K | Sale |
STEPHENSON BRIAN C |
Chief Financial Officer | — | Purchase |
Fundamentals
Market cap$694.85M
Enterprise value$509.00M
Revenue (TTM)—
Gross profit—
EBITDA$-36.64M
Net income$-195.53M
EPS (TTM)$-60.86
Free cash flow$855.13K
Total cash$186.44M
Total debt$592.00K
Book value / share$6.70
Shares outstanding25.84M
Float18.51M
Short % of float5.18%
Dividend yield0.00%
Beta (5Y)-0.29
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.99
PEG ratio—
Price / sales—
Price / book4.02
EV / revenue—
EV / EBITDA-13.89
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-195.26%
Return on assets-20.79%
Debt / equity0.34
Current ratio19.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $10.96M | $18.63M | $18.30M | $30.38M | -41.2% |
| Selling, general & admin | $11.33M | $13.04M | $18.77M | $19.80M | -13.1% |
| Total operating expense | $22.29M | $31.66M | $37.06M | $50.19M | -29.6% |
| Operating income | -$22.29M | -$31.66M | -$37.06M | -$50.19M | +29.6% |
| Net interest income | $1.21M | $2.46M | $3.48M | $1.56M | -50.9% |
| Pre-tax income | -$21.09M | -$30.16M | -$34.10M | -$48.59M | +30.1% |
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M | +30.1% |
| Net income to common | -$21.09M | -$30.16M | -$34.10M | -$48.59M | +30.1% |
| Basic EPS | -16.72 | -24.00 | -24.40 | -31.60 | +30.3% |
| Diluted EPS | -16.72 | -24.00 | -24.40 | -31.60 | +30.3% |
| EBIT | -$21.05M | -$30.07M | -$33.96M | -$48.37M | +30.0% |
| EBITDA | -$20.91M | -$28.75M | -$32.61M | -$47.02M | +27.2% |
| Basic shares | 1.26M | 1.26M | 1.40M | 1.54M | +0.4% |
| Diluted shares | 1.26M | 1.26M | 1.40M | 1.54M | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.67M | $9.99M | $13.01M | $17.80M | -13.3% |
| Cash & short-term investments | $21.18M | $41.34M | $65.76M | $107.12M | -48.8% |
| Total current assets | $21.51M | $41.93M | $67.25M | $108.59M | -48.7% |
| Property, plant & equipment | $1.38M | $3.38M | $7.04M | $9.72M | -59.3% |
| Total assets | $22.90M | $45.36M | $74.37M | $118.38M | -49.5% |
| Total current liabilities | $4.25M | $5.45M | $5.64M | $9.07M | -22.0% |
| Total debt | $1.51M | $3.85M | $6.21M | $8.03M | -60.8% |
| Total liabilities | $4.31M | $6.97M | $9.48M | $14.97M | -38.2% |
| Retained earnings | -$283.14M | -$262.05M | -$231.90M | -$197.79M | -8.0% |
| Shareholder equity | $18.59M | $38.39M | $64.89M | $103.41M | -51.6% |
| Working capital | $17.26M | $36.48M | $61.61M | $99.52M | -52.7% |
| Net tangible assets | $18.59M | $38.39M | $64.89M | $103.41M | -51.6% |
| Shares issued | 1.26M | 1.26M | 1.25M | 1.54M | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M | +30.1% |
| Depreciation & amortisation | $139.00K | $1.32M | $1.35M | $1.35M | -89.5% |
| Stock-based compensation | $1.27M | $3.13M | $4.45M | $5.81M | -59.4% |
| Change in working capital | -$1.59M | -$489.00K | -$4.33M | $1.01M | -225.6% |
| Operating cash flow | -$20.45M | -$24.67M | -$32.02M | -$39.03M | +17.1% |
| Capital expenditure | -$16.00K | -$146.00K | -$180.00K | -$321.00K | +89.0% |
| Investing cash flow | $19.77M | $22.44M | $38.41M | $49.95M | -11.9% |
| Share buybacks | -$1.00K | $0 | -$10.38M | $0 | — |
| Financing cash flow | -$645.00K | -$787.00K | -$11.17M | -$287.00K | +18.0% |
| Free cash flow | -$20.47M | -$24.82M | -$32.20M | -$39.35M | +17.5% |
| End cash position | $8.67M | $9.99M | $13.01M | $17.80M | -13.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $9.18M | $150.91M | $2.17M | $2.54M | $2.53M | — | -93.9% |
| Selling, general & admin | $9.21M | $19.71M | $2.79M | $2.31M | $2.67M | — | -53.3% |
| Total operating expense | $18.39M | $170.63M | $4.96M | $4.85M | $5.21M | — | -89.2% |
| Operating income | -$18.39M | -$170.63M | -$4.96M | -$4.85M | -$5.21M | — | +89.2% |
| Net interest income | $2.26M | $392.00K | $220.00K | $283.00K | $311.00K | — | +476.0% |
| Pre-tax income | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | — | +90.6% |
| Net income | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | — | +90.6% |
| Net income to common | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | — | +90.6% |
| Basic EPS | -2.84 | -131.45 | — | -3.62 | -3.91 | -5.45 | +97.8% |
| Diluted EPS | -2.84 | -131.45 | — | -3.62 | -3.91 | -5.45 | +97.8% |
| EBIT | -$18.39M | -$170.63M | -$4.71M | -$4.56M | -$5.21M | — | +89.2% |
| EBITDA | -$18.36M | -$170.60M | -$4.68M | -$4.53M | -$5.17M | — | +89.2% |
| Basic shares | 5.64M | 1.30M | — | 1.26M | 1.26M | 1.26M | +335.8% |
| Diluted shares | 5.64M | 1.30M | — | 1.26M | 1.26M | 1.26M | +335.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.90M | $152.32M | $8.67M | $10.56M | $12.56M | -82.3% |
| Cash & short-term investments | $186.44M | $202.79M | $21.18M | $25.04M | $28.63M | -8.1% |
| Total current assets | $188.66M | $204.23M | $21.51M | $25.79M | $29.57M | -7.6% |
| Property, plant & equipment | $568.00K | $982.00K | $1.38M | $1.79M | $2.19M | -42.2% |
| Total assets | $189.31M | $205.38M | $22.90M | $27.59M | $31.78M | -7.8% |
| Total current liabilities | $9.58M | $14.19M | $4.25M | $4.44M | $3.87M | -32.5% |
| Total debt | $592.00K | $1.04M | $1.51M | $2.02M | $2.56M | -43.1% |
| Total liabilities | $16.35M | $342.67M | $4.31M | $4.58M | $4.47M | -95.2% |
| Retained earnings | -$469.38M | -$453.37M | -$283.14M | -$278.42M | -$273.85M | -3.5% |
| Shareholder equity | $172.96M | -$137.29M | $18.59M | $23.01M | $27.31M | +226.0% |
| Working capital | $179.08M | $190.04M | $17.26M | $21.35M | $25.70M | -5.8% |
| Net tangible assets | $172.96M | -$137.29M | $18.59M | $23.01M | $27.31M | +226.0% |
| Shares issued | 25.83M | 1.34M | 1.26M | 1.26M | 1.26M | +1,827.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | +90.6% |
| Depreciation & amortisation | $25.00K | $30.00K | $34.00K | $34.00K | $37.00K | -16.7% |
| Stock-based compensation | $4.48M | $12.90M | $295.00K | $254.00K | $264.00K | -65.2% |
| Change in working capital | -$3.52M | $13.32M | $286.00K | $469.00K | -$1.49M | -126.4% |
| Operating cash flow | -$15.67M | -$10.73M | -$3.86M | -$3.59M | -$5.91M | -46.0% |
| Capital expenditure | — | -$6.00K | — | — | — | — |
| Investing cash flow | -$108.07M | -$31.44M | $2.08M | $1.74M | $8.76M | -243.8% |
| Share buybacks | -$1.76M | -$15.14M | $0 | $0 | -$1.00K | +88.4% |
| Financing cash flow | -$1.68M | $185.83M | -$111.00K | -$152.00K | -$168.00K | -100.9% |
| Free cash flow | -$15.67M | -$10.74M | -$3.86M | -$3.59M | -$5.92M | -45.9% |
| End cash position | $26.90M | $152.32M | $8.67M | $10.56M | $12.56M | -82.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -4.76 | -2.84 | +40.3% |
| Mar 2026 | -0.62 | -131.45 | -21,101.6% |
| Dec 2025 | -4.81 | -3.74 | +22.3% |
| Sep 2025 | -4.11 | -3.62 | +11.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.72 | 2 | $0 | 0.0% |
| Next quarter | -0.79 | 2 | $0 | 0.0% |
| Current year | -13.78 | 2 | $0 | 0.0% |
| Next year | -4.49 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$56.67
High target$70.00
Low target$46.00
Implied upside110.74%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 11
Hold0
Sell / Strong sell0 / 0
Held by insiders4.95%
Held by institutions79.64%
Institutions holding61
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
28.48
-5.58% from price
SMA 20
32.12
-16.28% from price
SMA 50
31.78
-15.39% from price
SMA 100
26.79
+0.37% from price
SMA 200
24.20
+11.13% from price
EMA 12
29.42
-8.61% from price
EMA 26
31.13
-13.62% from price
EMA 50
30.90
-12.98% from price
RSI (14)
35.9
Neutral
MACD (12,26,9)
-1.71
Hist -0.73
ATR (14)
2.36
8.78% of price
Realised vol 30D
76.8%
Annualised
Bollinger upper
40.15
20, 2σ
Bollinger lower
24.09
20, 2σ
50 / 200 cross
Golden
31.78 vs 24.20
Trend bias
Above 200
+11.13%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.73
More volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
76.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-69.2%
Peak to trough
Max drawdown 5Y
-97.1%
Peak to trough
ATR 14
2.36
8.78% of price
Beta (reported)
-0.29
5Y monthly, from filing
Short interest
Shares short
1.32M
Prior 827.17K
Change vs prior
+59.4%
Shorts adding
% of float
5.18%
Normal
% of shares out
5.10%
Against total outstanding
Days to cover
4.3
Liquid
Float
18.51M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | Guggenheim | INITIATED | — | Buy |
| Sep 14, 26 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Sep 9, 26 | TD Cowen | INITIATED | — | Buy |
| Aug 21, 26 | Needham | INITIATED | — | Buy |
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Jones Trading | INITIATED | — | Buy |
| Jul 31, 26 | Raymond James | INITIATED | — | Outperform |
| Jul 28, 26 | Oppenheimer | INITIATED | — | Outperform |
| Jul 20, 26 | Citizens | INITIATED | — | Market Outperform |
| Jul 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 26, 26 | Baird | INITIATED | — | Outperform |
| Jun 22, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateJun 17, 2025
SEC filings
Headlines
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
MarketBeat · 2h ago
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Business Wire · 20d ago
Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
MT Newswires · 21d ago
TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
MT Newswires · 28d ago
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Business Wire · 29d ago
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Zacks · 36d ago
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Business Wire · 36d ago
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 40d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.